Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
To assess the pattern and possible risk factors of conventional and/or pegylated interferon alpha (IFN-α) plus ribavirin therapy for causing adverse reactions in patients with chronic hepatitis C virus. Patients attending a referral center in Iran were assessed. During an 18 month period all adult individuals diagnosed with chronic hepatitis C virus who planned to receive anti-hepatitis C virus treatment were prospectively screened regarding all related subjective and objective adverse drug reactions. The number of adverse drug reactions were significantly associated with the number of concomitant medications (p < 0.001), female gender (p = 0.027), increased age (p = 0.001), pegylated IFN-α (p = 0.015) and hepatitis C virus genotype 1 (p = 0.002). History of a prior anti-hepatitis C virus treatment course (OR = 3.081, 95% CI = 1.174 - 6.085; p = 0.022) and the number of co-administered medications (OR = 1.165, 95% CI = 1.034 - 1.314; p = 0.012) were identified as the only statistically significant risk factors for developing anti-hepatitis C virus medication-related psychiatric and dermatologic adverse reactions, respectively. These data could be exploited by health-care professionals and policy makers as a guide for developing optimal educational and preventive strategies in the setting of anti-hepatitis C virus medication safety.